Synergistic effect of cyclodextrins and electrolytes at high concentrations on protein aggregation inhibition

drug delivery, Today's cyclodextrin, ,

Today’s cyclodextrin is about preventing protein aggregation.

I have posted a lot about how CDs can interact with proteins, CarboHyde even shared an educative deck on this earlier: CDs_in_protein_formulations.pdf

The research below from Kobe University and synplogen adds a new feature to this knowledge via exploring the Synergistic effect of cyclodextrins and electrolytes at high concentrations on protein aggregation inhibition:
Synergistic effect of cyclodextrins and electrolytes at high concentrations on protein aggregation inhibition – Journal of Pharmaceutical Sciences

Research highlights:
•High cyclodextrin (CD) and electrolyte concentrations synergistically stabilize biopharmaceutical proteins.
•HP-β-CD and Arg-HCl significantly increase the onset temperature of protein aggregation of immunoglobulin G, insulin, and adeno-associated virus vectors.
•This synergistic effect was not observed when sucrose was used instead of HP-β-CD.
•HP-β-CD and Arg-HCl combination effectively inhibits the formation of soluble and insoluble IgG aggregates during long-term storage.

Cyclodextrin Dimers  Functionalized with Biotin as Nanocapsulesfor Active Doxorubicin Delivery against MCF-7 Breast Cell Line

Today's cyclodextrin

Today’s cyclodextrin showcases versatility.

Graziella Vecchio‘s team presents the use of Cyclodextrin dimers as potential nanocapsules of biomolecules. The presence of two cavities can improve the stability of inclusion complexes, working as a hydrophilic sandwich of poorly water-soluble species.

The building blocks were functionalized with biotin as a targeting unit and tested the new bioconjugates as doxorubicin delivery systems in cancer cells.

Great work, Noemi Bognanni!

Cyclodextrin Dimers  Functionalized with Biotin as Nanocapsulesfor Active Doxorubicin Delivery against MCF‐7 Breast Cell Line – Bognanni – ChemMedChem – Wiley Online Library

Gilead Donates Remdesivir for Emergency Use in Response to Marburg Virus Disease in Rwanda

Today's cyclodextrin

Today’s cyclodextrin:
Gilead Sciences announced that it will donate approximately 5,000 vials of remdesivir to the Rwanda Medical Supply in conjunction with the Ministry of Health of the Republic of Rwanda and the Africa Centers for Disease Control for emergency use in response to the Marburg Virus Disease (MVD) outbreak.

Not many know, yet Veklury (SBECD+remdesivir), which was the first drug approved against Covid-19, was originally developed against the Marburg virus and later also saved the lives of Ebola-infected people.

Remdesivir is being provided for the treatment of MVD in Rwanda for emergency use. Remdesivir is not approved for the treatment of MVD anywhere globally, and the safety and efficacy of this use is not known.

Remdesivir is a nucleotide analog prodrug invented and developed by Gilead, building on more than a decade of the company’s antiviral research. Remdesivir has broad-spectrum antiviral activity both in vitro and in animal models against multiple viral pathogens, including Marburg, Ebola, SARS, MERS and SARS-CoV-2, the virus that causes COVID-19.

Remdesivir has been approved as a COVID-19 treatment in approximately 50 countries worldwide. To date, remdesivir has been made available to more than 14 million patients around the world, including more than 8 million people in middle- and low-income countries through Gilead’s voluntary licensing program.

Gilead Donates Remdesivir for Emergency Use in Response to Marburg Virus Disease in Rwanda

Happy Halloween with cyclodextrin :)

Today's cyclodextrin,

Halloween perfumes
Cyclodextrins are often used in various cosmetic products, including perfumes. These “Halloween specials” contain methyl-beta-cyclodextrin as functional excipients as stabilizer, to improve performance and sensation.
Halloween Perfumes – Manufacturers – MT Shop

Pumpkin lutein stabilization
Lutein is an important nutrient element, and its health benefits are gradually being recognized. Lutein, as a carotenoid antioxidant, can protect cells and organs from damage caused by free radicals. However, in processing, storage, and usage, lutein is unstable and often undergoes isomerization and oxidative decomposition, which limits its wide range of applications.
The β-cyclodextrin microcapsule can ensure that lutein maintains a more stable state under acidic, light, and other adverse conditions.

Improvement in the stability and bioavailability of pumpkin lutein using β‐cyclodextrin microcapsules – Shi – 2023 – Food Science & Nutrition – Wiley Online Library

EuroCD 2025 – 8th European Cyclodextrin Conference

Today's cyclodextrin,

Today’s cyclodextrin is the first announcement of EUROCD25:

Save the date! We are happy to announce the 8th European Cyclodextrin Conference EuroCD2025, which will take place in Milan, Italy, from September 9 to 12, 2025.

Join us for this unique opportunity to exchange ideas with scholars worldwide and explore the innovative research, processes, methodologies, and applications that continue to shape the field of cyclodextrin chemistry.

We’re also excited to host the inaugural Thorsteinn Loftsson Award for cyclodextrin chemistry!
Visit our website to learn more about submitting a nomination.
EuroCD 2025 – 8th European Cyclodextrin Conference (9-12 September 2025): OVERVIEW · Indico Event Management @ DCMC – Politecnico di Milano (Indico)

Abstract submission is open. Please use the downloadable template and send your abstract via email only to eurocd2025@polimi.it.


We are looking forward to seeing you in Milan!

Andrea Mele & Francesco Trotta – Conference Chairs

Welcoming Fahad Khan Tareen from Università di Pavia: Collaborating on Innovative Drug Delivery with Cyclodextrins!

news

While some of our members enjoy secondments in Argentina and Leuven, we have the pleasure to host Fahad Khan Tareen from Università di Pavia Cristina Bonferoni‘s lab.

Fahad works with Balázs on some unique drug delivery applications with cyclodextrins (surprise!) and stays with us until next January.

It’s such a pleasure to work with so diligent and bright scientists, eager to learn and innovate.

Exceptional stability of the sugammadex-solasodine complex: Insights from experimental and theoretical studies

drug development

A new paper out!

Sugammadex (SGM) is the first cyclodextrin (CD)-based selective relaxant binding agent. We investigated its ability to capture natural aminosteroid phytotoxins, and assessed its potential as an antidote for intoxication.

SGM significantly increased cell survival and reduced Solasodine (the toxic alkaloid chosen as model compound) toxicity in mHippoE-14 mouse hippocampal embryonic cells, supporting the hypothesis that SGM could act as an antidote to SS’s toxic effects.

Special thanks for the fantastic teamwork:
Eszter Kalydi – Semmelweis University
Fanni Sebák, Éva Moussong József Kardos, Andrea Bodor Szabolcs Béni – Eötvös Loránd University
Béla Fiser – University of Miskolc
Babak Minofar – University of Lodz
Milo Malanga PhD – CarboHyde

Exceptional stability of the sugammadex-solasodine complex: Insights from experimental and theoretical studies – ScienceDirect

Want to play with Sugammadex in AR?

drug discovery, news,

We are happy to share this little beta version game that Balázs Attila Kondoros and Kristóf Felegyi put together during their Bicyclos HEurope secondment. Special thanks for the support and guidance of Angel Piñeiro and Rebeca Garcia-Fandino for their amazing work.

Molvelle AR Software was developed within the framework of the European Bicyclos project (EC-funded Staff Exchange project n° 101130235) in collaboration with the University of Santiago de Compostela, MD.USE Innovative Solutions S.L., Carbohyde, and IES Rosalía de Castro, Santiago de Compostela.

Enjoy!

Molvelle Ar en App Store

Impact of Methylated Cyclodextrin KLEPTOSE® CRYSMEB on Inflammatory Responses in Human In Vitro Models

Today's cyclodextrin

today’s cyclodextrin is a fanstastic study from dear friend Damien TRUFFIN from Roquette about the Impact of Methylated Cyclodextrin on Inflammatory Responses.

The results showed that KLEPTOSE® CRYSMEB can modulate the immune system in vitro and potentially manage vascular issues by stimulating the expression of molecules involved in the crosstalk between immune cells and other cell types.

It showed anti-inflammatory effects that were driven by the inhibition of pro-inflammatory cytokine secretion and could have different impacts on different tissue types.

Moreover, this cyclodextrin showed no clear impact on pro-resolving lipid mediators.

Additionally, it appeared that the mechanism of action of KLEPTOSE® CRYSMEB seems to not be shared by other well-known anti-inflammatory molecules.

Finally, KLEPTOSE® CRYSMEB may have an anti-inflammatory impact, which could be due to its effect on receptors such as TLR or direct complexation with LPS or PGE2, and conversely, this methylated cyclodextrin could stimulate a pro-inflammatory response involving lipid mediators and on proteins involved in communication with immune cells, probably via interaction with membrane cholesterol.

Impact of Methylated Cyclodextrin KLEPTOSE® CRYSMEB on Inflammatory Responses in Human In Vitro Models